Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium animalis subsp. lactis MN-Gup
- Development stage
- Unknown
- Lead developer
- Mengniu
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
MN-Gup is a specific probiotic strain of *Bifidobacterium animalis* subsp. *lactis* developed for the management of metabolic disorders, particularly Type 2 Diabetes Mellitus (T2DM). It functions as a live biotherapeutic that modulates the host's gut microbiota composition. This modulation leads to altered levels of serum bile acids (such as deoxycholic acid and lithocholic acid) and increased secretion of the incretin hormone glucagon-like peptide-1 (GLP-1). These systemic changes contribute to improved glycemic control, reduced inflammation, and decreased oxidative stress. In clinical trials, MN-Gup has been evaluated both as a monotherapy and as part of a synbiotic mixture with galactooligosaccharides (GOS), where the synbiotic formulation (MN-Gup-GOS) demonstrated enhanced efficacy in lowering fasting blood glucose and improving insulin resistance.
- Other names
- Bifidobacterium animalis subsp. lactis MN-Gup
02
Targets
Beyond the preview
Go deeper on Bifidobacterium animalis subsp. lactis MN-Gup.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium animalis subsp. lactis MN-Gup.